Gene · 9436
Papers3,322
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,322
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Endogenous Signaling Molecule Activating (ESMA) CARs: A Novel CAR Design Showing a Favorable Risk to Potency Ratio for the Treatment of Triple Negative Breast Cancer. | Int J Mol Sci | 2024 | 38203786 | PubTator, text mining | PubMed |
| Cutting Edge: PDGF-DD Binding to NKp44 Costimulates TLR9 Signaling and Proinflammatory Cytokine Secretion in Human Plasmacytoid Dendritic Cells. | J Immunol | 2024 | 38117750 | PubTator, text mining | PubMed |
Characterization of the complete mitochondrial genomes of the zoonotic parasites Bolbosoma nipponicum and Corynosoma villosum (Acanthocephala: Polymorphida) and the molecular phylogeny of the order Polymorphida. | Parasitology | 2024 | 37955106 | PubTator, text mining | PubMed |
| WTAP enhances the instability of SYTL1 mRNA caused by YTHDF2 in bladder cancer. | Histol Histopathol | 2024 | 37933909 | PubTator, text mining | PubMed |
| HLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells. | Gut | 2024 | 37788895 | PubTator, text mining | PubMed |
| Contribution of the TIME in BCP-ALL: the basis for novel approaches therapeutics. | Front Immunol | 2023 | 38299154 | PubTator, text mining | PubMed |
Overcoming cancer risk in inflammatory bowel disease: new insights into preventive strategies and pathogenesis mechanisms including interactions of immune cells, cancer signaling pathways, and gut microbiota. | Front Immunol | 2023 | 38288125 | PubTator, text mining | PubMed |
| Persistence of KIRneg NK cells after haploidentical hematopoietic stem cell transplantation protects from human cytomegalovirus infection/reactivation. | Front Immunol | 2023 | 38268918 | PubTator, text mining | PubMed |
| Harnessing Immunity to Treat Advanced Thyroid Cancer. | Vaccines (Basel) | 2023 | 38250858 | PubTator, text mining | PubMed |
| The role of natural killer T cells in liver transplantation. | Front Cell Dev Biol | 2023 | 38250325 | PubTator, text mining | PubMed |
| Immunoregulatory functions and therapeutic potential of natural killer cell-derived extracellular vesicles in chronic diseases. | Front Immunol | 2023 | 38239346 | PubTator, text mining | PubMed |
| NK3.3-Derived Extracellular Vesicles Penetrate and Selectively Kill Treatment-Resistant Tumor Cells. | Cancers (Basel) | 2023 | 38201518 | PubTator, text mining | PubMed |
| Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms. | Front Immunol | 2023 | 38193082 | PubTator, text mining | PubMed |
| Ovarian cancer treatment and natural killer cell-based immunotherapy. | Front Immunol | 2023 | 38187402 | PubTator, text mining | PubMed |
| Hepatitis D infection induces IFN-β-mediated NK cell activation and TRAIL-dependent cytotoxicity. | Front Immunol | 2023 | 38143742 | PubTator, text mining | PubMed |
| The Role of NKG2D and Its Ligands in Autoimmune Diseases: New Targets for Immunotherapy. | Int J Mol Sci | 2023 | 38139373 | PubTator, text mining | PubMed |
| Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells. | Int J Mol Sci | 2023 | 38139060 | PubTator, text mining | PubMed |
| CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. | Biomedicines | 2023 | 38137547 | PubTator, text mining | PubMed |
Biomarkers in Adult-Type Diffuse Gliomas: Elevated Levels of Circulating Vesicular Heat Shock Protein 70 Serve as a Biomarker in Grade 4 Glioblastoma and Increase NK Cell Frequencies in Grade 3 Glioma. | Biomedicines | 2023 | 38137456 | PubTator, text mining | PubMed |
| Unlocking Glioblastoma Secrets: Natural Killer Cell Therapy against Cancer Stem Cells. | Cancers (Basel) | 2023 | 38136381 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9436/papers?page=7